Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genfit SA ( (GNFT) ) has shared an announcement.
On May 22, 2025, GENFIT reported its financial results for the first quarter of 2025, highlighting a significant increase in cash reserves due to a €130 million installment from a royalty financing agreement with HCRx. This financial boost, alongside anticipated milestone revenues from Ipsen, extends GENFIT’s cash runway beyond 2027, supporting its R&D efforts in ACLF and other programs. The company’s revenues for the first quarter of 2025 increased to €2.8 million, primarily from royalties on Ipsen’s sales of Iqirvo®. Additionally, GENFIT announced the upcoming retirement of its Chief Medical Officer, Carol Addy, effective June 30, 2025.
The most recent analyst rating on (GNFT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score of 59 reflects a blend of significant financial recovery and positive technical momentum, indicating a promising direction for the company. However, the high P/E ratio suggests that the stock may be overvalued, which is a key risk factor. While the financial performance shows improvement, the need for better operational efficiency and more balanced capital structure remain areas for improvement to support long-term growth.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases, with a strong emphasis on Acute-on-Chronic Liver Failure (ACLF). The company has a diverse R&D portfolio, including assets targeting cholangiocarcinoma, urea cycle disorder, and organic acidemia. GENFIT is known for its expertise in developing high-potential molecules and has a diagnostic franchise in metabolic dysfunction-associated steatohepatitis.
Average Trading Volume: 13,632
Technical Sentiment Signal: Buy
Current Market Cap: $217.1M
For a thorough assessment of GNFT stock, go to TipRanks’ Stock Analysis page.